These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15357972)

  • 1. Synthesis and DP-IV inhibition of cyano-pyrazoline derivatives as potent anti-diabetic agents.
    Ahn JH; Kim HM; Jung SH; Kang SK; Kim KR; Rhee SD; Yang SD; Cheon HG; Kim SS
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4461-5. PubMed ID: 15357972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors.
    Ahn JH; Kim JA; Kim HM; Kwon HM; Huh SC; Rhee SD; Kim KR; Yang SD; Park SD; Lee JM; Kim SS; Cheon HG
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1337-40. PubMed ID: 15713382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.
    Yasuda N; Nagakura T; Inoue T; Yamazaki K; Katsutani N; Takenaka O; Clark R; Matsuura F; Emori E; Yoshikawa S; Kira K; Ikuta H; Okada T; Saeki T; Asano O; Tanaka I
    Eur J Pharmacol; 2006 Oct; 548(1-3):181-7. PubMed ID: 16973152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines.
    Soroka A; Van der Veken P; De Meester I; Lambeir AM; Maes MB; Scharpé S; Haemers A; Augustyns K
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4777-9. PubMed ID: 16844373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
    Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.
    Pei Z; Li X; Longenecker K; von Geldern TW; Wiedeman PE; Lubben TH; Zinker BA; Stewart K; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Long M; Wells H; Kempf-Grote AJ; Madar DJ; McDermott TS; Bhagavatula L; Fickes MG; Pireh D; Solomon LR; Lake MR; Edalji R; Fry EH; Sham HL; Trevillyan JM
    J Med Chem; 2006 Jun; 49(12):3520-35. PubMed ID: 16759095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Augeri DJ; Robl JA; Betebenner DA; Magnin DR; Khanna A; Robertson JG; Wang A; Simpkins LM; Taunk P; Huang Q; Han SP; Abboa-Offei B; Cap M; Xin L; Tao L; Tozzo E; Welzel GE; Egan DM; Marcinkeviciene J; Chang SY; Biller SA; Kirby MS; Parker RA; Hamann LG
    J Med Chem; 2005 Jul; 48(15):5025-37. PubMed ID: 16033281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors.
    Belyaev A; Zhang X; Augustyns K; Lambeir AM; De Meester I; Vedernikova I; Scharpé S; Haemers A
    J Med Chem; 1999 Mar; 42(6):1041-52. PubMed ID: 10090787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV.
    Nordhoff S; López-Canet M; Hoffmann-Enger B; Bulat S; Cerezo-Gálvez S; Hill O; Rosenbaum C; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4818-23. PubMed ID: 19576767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Derivatives of pyrazole-l-carboxylic acid. VII. Synthesis and hypoglycemic properties of various N-(4-[2-(alkyl-2-pyrazoline-1-carbonamido)-ethyl]-benzenesulfonyl)-N'-cyclohexylurea].
    Brzozowski Z; Magiełka S; Wójcikowski C
    Acta Pol Pharm; 1983; 40(2):134-8. PubMed ID: 6659996
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis and biological evaluation of pyrazoline analogues with beta-amino acyl group as dipeptidyl peptidase IV inhibitors.
    Jun MA; Park WS; Kang SK; Kim KY; Kim KR; Rhee SD; Bae MA; Kang NS; Sohn SK; Kim SG; Lee JO; Lee DH; Cheon HG; Kim SS; Ahn JH
    Eur J Med Chem; 2008 Sep; 43(9):1889-902. PubMed ID: 18243422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
    Brandt I; Joossens J; Chen X; Maes MB; Scharpé S; De Meester I; Lambeir AM
    Biochem Pharmacol; 2005 Jul; 70(1):134-43. PubMed ID: 15907807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
    Brigance RP; Meng W; Fura A; Harrity T; Wang A; Zahler R; Kirby MS; Hamann LG
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4395-8. PubMed ID: 20598534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoro-olefins as peptidomimetic inhibitors of dipeptidyl peptidases.
    Van der Veken P; Senten K; Kertèsz I; De Meester I; Lambeir AM; Maes MB; Scharpé S; Haemers A; Augustyns K
    J Med Chem; 2005 Mar; 48(6):1768-80. PubMed ID: 15771423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.
    Connolly BA; Sanford DG; Chiluwal AK; Healey SE; Peters DE; Dimare MT; Wu W; Liu Y; Maw H; Zhou Y; Li Y; Jin Z; Sudmeier JL; Lai JH; Bachovchin WW
    J Med Chem; 2008 Oct; 51(19):6005-13. PubMed ID: 18783201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An example of designed multiple ligands spanning protein classes: dual MCH-1R antagonists/DPPIV inhibitors.
    Gattrell WT; Sambrook Smith CP; Smith AJ
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2464-9. PubMed ID: 22377519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors.
    Caldwell CG; Chen P; He J; Parmee ER; Leiting B; Marsilio F; Patel RA; Wu JK; Eiermann GJ; Petrov A; He H; Lyons KA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1265-8. PubMed ID: 14980678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
    J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazolidine derivatives with heteroaryl urea as dipeptidyl peptidase IV inhibitors.
    Ahn JH; Jung SH; Kim JA; Song SB; Kwon SJ; Kim KR; Rhee SD; Park SD; Lee JM; Kim SS; Cheon HG
    Chem Pharm Bull (Tokyo); 2005 Aug; 53(8):1048-50. PubMed ID: 16079547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.